In-Depth Analysis of MANGALAM (NSE: MANGALAM)Technical Overview:
1. Support at Rising Trendline:
MANGALAM has found consistent support at a rising trendline on the weekly chart. This indicates a level where buying interest has historically emerged, suggesting potential bullish sentiment.
2. Breakout at RSI Divergence:
The breakout obs
−10.75INR
12.70 MINR
3.71 BINR
13.43 M
About MANGALAM DRUGS & O
Sector
CEO
Govardhan Murlidhar Dhoot
Headquarters
Mumbai
Website
Employees (FY)
523
Founded
1972
ISIN
INE584F01014
FIGI
BBG000F8CMX7
Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. Its products include Acyclovir, Amodiaquine HCI, Bisoprolol Fumarate, Furosemide, Tenofovir Disoproxil Base, Lumefantrine, Bictegravir Sodium and Artemether. The company was founded in 1972 and is headquartered in Mumbai, India.
MEDIUM TERM INVESTMENT PICK : BUY MANGALAMStock should five Valid KBO Setup Next week. Entry Will be Triggered above 202.40 STOP CANDLE CLOSE BELOW KS LOW.
Target 282/320/If Sustains above 320 for 2 Consecutive Days then Big Rally to come/529/640
Stock formed Bullish Divergence and Price did try to push up a bit and resulting to a failur
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MANGALAM is 99.15 INR — it has decreased by 0.80% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange MANGALAM DRUGS & O stocks are traded under the ticker MANGALAM.
MANGALAM DRUGS & O is going to release the next earnings report on May 30, 2024. Keep track of upcoming events with our Earnings Calendar.
MANGALAM stock is 3.86% volatile and has beta coefficient of 0.64. Check out the list of the most volatile stocks — is MANGALAM DRUGS & O there?
Yes, you can track MANGALAM DRUGS & O financials in yearly and quarterly reports right on TradingView.
MANGALAM stock has fallen by 3.97% compared to the previous week, the month change is a 0.86% rise, over the last year MANGALAM DRUGS & O has showed a 13.33% decrease.
MANGALAM net income for the last quarter is 4.98 M INR, while the quarter before that showed −35.64 M INR of net income which accounts for 113.97% change. Track more MANGALAM DRUGS & O financial stats to get the full picture.
Today MANGALAM DRUGS & O has the market capitalization of 1.59 B, it has increased by 4.76% over the last week.
MANGALAM DRUGS & O dividend yield was 0% in 2022, and payout ratio reached 0%. The year before the numbers were 0% and 0% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, MANGALAM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MANGALAM DRUGS & O stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 523.00 employees. See our rating of the largest employees — is MANGALAM DRUGS & O on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MANGALAM DRUGS & O technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MANGALAM DRUGS & O stock shows the sell signal. See more of MANGALAM DRUGS & O technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MANGALAM DRUGS & O EBITDA is 59.22 M INR, and current EBITDA margin is 7.03%. See more stats in MANGALAM DRUGS & O financial statements.